Avia Logo

Compare Products


Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
Jump to:
Categories
Solutions
Description
Compatibility Level
Clients
Use cases
EHR integrations
Client types
Differentiators
Keywords
Media
Company details
reSET® & reSET-O®
reSET® & reSET-O®

0 review

Categories

Solutions

Description

Product Description:

reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day Prescription Digital Therapeutic (PDT) for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

About Pear Therapeutics, Inc.:
Pear Therapeutics, Inc. is a venture-backed digital health company focused on the development of digital therapies and drug/software combinations to treat diseases with high unmet medical need.  PEAR's patented, clinically validated approach is designed to provide enhanced outcomes for patients, actionable data for clinicians, and cost-effective solutions for payers.
Product Description:

Our clinically proven mental health solution quickly connects people to the right kind of care.

About DarioHealth:
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company focused on innovative approaches to driving durable behavior change in chronic disease, to positively impact health outcomes and cost of care. Dario creates durable behavior change in chronic conditions. For individuals facing the challenges of diabetes, prediabetes, hypertension, obesity, and other chronic conditions, Dario delivers highly personalized digital interactions, actionable data, engaging digital tools and easy to use monitoring devices plus human support. Combined, these touch points make doing the "right thing the easy thing" by encouraging proactive, positive behavior changes that lead to improved health outcomes. Dario chronic condition digital therapeutics solution and the MyDario™ mobile app is loved and recommended by close to 100,000 users around the globe--with a 4.9 star rating across 11,000 reviews on the Apple App Store, and world-class Net Promoter Score (NPS) of 77.

Compatibility level

Select which hospital or health system you work at and see a personalized compatibility level.

Clients

Select which hospital or health system you work at and see the client list

Use Cases

Description:

We are developing PDTs to treat patients suffering from a range of serious diseases. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.

Pediatric use cases:

None provided

Users:

Patients with multiple serious diseases.

Description:

None provided

Pediatric use cases:

None provided

Users:

None provided

EHR Integrations

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Integrations:

None provided

EMR Integration & Relevant Hardware:

None provided

EMRs Supported:

None provided

Hardware Compatibility:

None provided

Client Types

None provided

Differentiators

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.

Differentiators vs EHR Functionality:

None provided

Differentiators vs Competitors:

None provided

Keywords

Images

1 of 3

edit-media

No images provided

Videos

No videos provided

No videos provided

Downloads

No content provided

No content provided

Alternatives

Company Details

Founded in 2013

Founded in 2011

team illustration
Share your product comparison with your collegues.

Need help narrowing down products?

Add more criteria to see your compatibility level for every vendor. It only takes a few minutes, just create a free account to get started.
back to top